Eads & Heald Wealth Management increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 20.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,175 shares of the medical research company’s stock after acquiring an additional 547 shares during the quarter. Eads & Heald Wealth Management’s holdings in Charles […]
Clear Harbor Asset Management LLC bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,025 shares of the medical research company’s stock, valued at approximately $397,000. Other […]
North Growth Management Ltd. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 15.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,000 shares of the medical research company’s stock after purchasing an additional 5,000 shares during the […]
Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) saw a large decrease in short interest in November. As of November 30th, there was short interest totalling 1,470,000 shares, a decrease of 9.8% from the November 15th total of 1,630,000 shares. Based on an average trading volume of 532,900 shares, the short-interest ratio is […]
Charles River Laboratories International (NYSE:CRL – Free Report) had its price target raised by Citigroup from $190.00 to $215.00 in a report issued on Monday morning, Benzinga reports. They currently have a neutral rating on the medical research company’s stock. Other analysts have also issued research reports about the company. Evercore ISI decreased their price […]